Radium

"Radium" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A radioactive element of the alkaline earth series of metals. It has the atomic symbol Ra and atomic number 88. Radium is the product of the disintegration of URANIUM and is present in pitchblende and all ores containing uranium. It is used clinically as a source of beta and gamma-rays in radiotherapy, particularly BRACHYTHERAPY.

Descriptor ID	D011883
MeSH Number(s)	D01.268.271.770 D01.268.552.775 D01.268.556.775 D01.496.749.305.770 D01.552.539.745 D01.552.544.775
Concept/Terms	Radium Radium

Below are MeSH descriptors whose meaning is more general than "Radium".

Chemicals and Drugs [D]
Inorganic Chemicals [D01]
Elements [D01.268]
Elements, Radioactive [D01.268.271]
Radium [D01.268.271.770]
Metals, Alkaline Earth [D01.268.552]
Radium [D01.268.552.775]
Metals, Heavy [D01.268.556]
Radium [D01.268.556.775]
Isotopes [D01.496]
Radioisotopes [D01.496.749]
Elements, Radioactive [D01.496.749.305]
Radium [D01.496.749.305.770]
Metals [D01.552]
Metals, Alkaline Earth [D01.552.539]
Radium [D01.552.539.745]
Metals, Heavy [D01.552.544]
Radium [D01.552.544.775]

Below are MeSH descriptors whose meaning is more specific than "Radium".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Radium" by people in this website by year, and whether "Radium" was a major or minor topic of these publications.

Bar chart showing 18 publications over 9 distinct years, with a maximum of 4 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2014	2	0	2
2015	1	1	2
2016	2	1	3
2017	2	2	4
2018	1	0	1
2020	3	0	3
2021	1	0	1
2022	1	0	1
2023	1	0	1

Below are the most recent publications written about "Radium" by people in Profiles.

Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59.

View in: PubMed
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandstr?m P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer Prostatic Dis. 2022 02; 25(2):306-313.

View in: PubMed
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandstr?m P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncol. 2022 Jan; 18(1):35-45.

View in: PubMed
Hurwitz M, Buscombe JR, Jacene HA, Klitzke AK, Lamonica D, Lu Y, Pryma DA, Rohren EM, Speer TW, Subramaniam RM, Thompson HM, Tomblyn MB, Wong WW, Xiao Y, Banks KP, Brown RKJ. ACR-ACNM-ASTRO-SNMMI Practice Parameter for the Performance of Therapy With Radium-223. Am J Clin Oncol. 2020 08; 43(8):539-544.

View in: PubMed
Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 12; 23(4):680-688.

View in: PubMed
Shore ND, Schellhammer PF, Tutrone RF, Mariados NF, Harrelson SS. Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 10; 18(5):416-422.

View in: PubMed
Parker C, Heidenreich A, Nilsson S, Shore N. Current approaches to incorporation of radium-223 in clinical practice. Prostate Cancer Prostatic Dis. 2018 04; 21(1):37-47.

View in: PubMed
Sartor O, Vogelzang NJ, Sweeney C, Fernandez DC, Almeida F, Iagaru A, Brown A, Smith MR, Agrawal M, Dicker AP, Garcia JA, Lutzky J, Wong YN, Petrenciuc O, Gratt J, Shore ND, Morris MJ. Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist. 2018 02; 23(2):193-202.

View in: PubMed
Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS. eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2018 04; 16(2):149-154.

View in: PubMed
Dan TD, Eldredge-Hindy HB, Hoffman-Censits J, Lin J, Kelly WK, Gomella LG, Lallas CD, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies. Am J Clin Oncol. 2017 Aug; 40(4):342-347.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement